FLSM
REPL icon

Frazier Life Sciences Management’s Replimune Group REPL Stock Holding History

Frazier Life Sciences Management’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-386,762
Closed -$6.62M – 54
2023
Q3 		$6.62M Hold
386,762
– – 0.44% 38
2023
Q2 		$8.98M Sell
386,762
-300,000
-44% -$5.86M 0.54% 33
2023
Q1 		$12.1M Sell
686,762
-244,798
-26% -$5.82M 0.88% 28
2022
Q4 		$25.3M Buy
931,560
+125,293
+16% +$2.6M 1.58% 17
2022
Q3 		$13.9M Hold
806,267
– – 1.07% 23
2022
Q2 		$14.1M Buy
806,267
+89,505
+12% +$1.47M 1.33% 21
2022
Q1 		$12.2M Buy
+716,762
New +$13.5M 1.04% 31

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return